26. Eur J Surg Oncol. 2018 Aug;44(8):1157-1163. doi: 10.1016/j.ejso.2018.03.018. Epub2018 Mar 31.Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society ofSurgical Oncology (SICO) Breast Oncoteam survey.Vicini E(1), Invento A(2), Cuoghi M(3), Bafile A(4), Battaglia C(5), Biglia N(6),Busani M(7), Bussone R(8), Cianchetti E(9), Caruso F(10), Cucchi MC(3), DessenaM(11), Di Filippo F(12), Fabi N(12), Folli S(13), Friedman D(14), MacellariG(15), Mainente P(16), Murgo R(17), Neri A(18), Pollini GP(2), Palli D(19), RicciF(20), Scalco G(21), Taffurelli M(22), Trunfio M(23), Galimberti V(24); ItalianSociety of Surgical Oncology (SICO) Breast Oncoteam.Author information: (1)Division of Breast Surgery, European Institute of Oncology, Milan, Italy.Electronic address: elisa.vicini@hotmail.it.(2)U.O.C. Breast Unit AOUI Borgo Trento, Verona, Italy.(3)U.O.S.D. Chirurgia Senologica Breast Unit Bellaria USL Bologna, Italy.(4)Division of Breast Surgery, Ospedale San Salvatore Coppito, L'Aquila, Italy.(5)Unit of Senology Ospedale Civile di Sanremo, Italy.(6)Università di Torino, Osp. Mauriziano Umberto I, Torino, Italy.(7)SSD di Chirurgia Senologica, Az. Osp. " C. Poma ", Mantova, Italy.(8)Chirurgia Senologica-Breast Unit, Ospedale Cottolengo, Torino, Italy.(9)Chirurgia generale a indirizzo Senologico, Ospedale Gaetano Bernabeo, Ortona, CH, Italy.(10)Breast Centre Humanitas, Catania, Italy.(11)S.C. Chirurgia Sperimentale, Ospedale Oncologico, Azienda Ospedaliera Brotzu,Cagliari, Italy.(12)Regina Elena National Cancer Institute, Roma, Italy.(13)AUSL Romagna, Ospedale GB Morgagni S.C. di Senologia, Forlì, FC, Italy.(14)U.O. Chirurgia Senologica, Ospedale Policlinico San Martino, Genova, Italy.(15)Breast Centre Ospedale S. Giuseppe, Milano, Italy.(16)UOS Senologia c/o S.C. di Chirurgia Generale, Ospedale "Alto Vicentino" -ULSS 7 PEDEMONTANA - Santorso, Vicenza, Italy.(17)UOC di Chirurgia Senologica, Ospedale IRCCS Casa Sollievo della Sofferenza,San Giovanni Rotondo, FG, Italy.(18)Centro Senologico AOU Senese, Policlinico Le Scotte, Siena, Italy.(19)U.O.S.D. di Chirurgia Senologia-Breast Unit Ospedale "Guglielmo da Saliceto",Piacenza, Italy.(20)Breast Unit "S. M. Goretti" Hospital, ASL-Latina/Sapienza University of Rome,Polo Pontino, Latina, Italy.(21)U.O.S. di Senologia Chirurgica, U.O.C. di Chirurgia Generale, Ospedale SanBortolo, Vicenza, Italy.(22)Dipartimento di Medicina e Chirurgia (DIMEC), Università di Bologna,Policlinico di Sant'Orsola, Bologna, Italy.(23)Dipartimento di Senologia Chirurgica, Azienda Ospedaliera A. Cardarelli,Napoli, Italy.(24)Division of Breast Surgery, European Institute of Oncology, Milan, Italy.The Italian Society of Surgical Oncology (SICO) Breast Oncoteam developed asurvey to explore the state of the art of neoadjuvant treatment for breast cancerin Italy, specifically focusing on cases treated during the two-year period2014-2015. A questionnaire was sent to Italian Breast Units with a minimum of 150new breast cancer cases treated/year according to the Senonetwork directory andto the SICO Breast Oncoteam Breast Unit network. A total of 23/107 Breast Unitssubmitted the survey, reporting a total amount of 20156 cases of breast carcinoma(17241 invasive, 2915 in situ) treated in the biennium, correspondingapproximately to 20% of newly diagnosed breast cancers in Italy. In the UnitedStates, medical treatment before surgery for breast cancer is indicated in about 22.7% of newly diagnosed cases according to the National Cancer Database, while aGerman study reported approximately 20% of cases treated with neoadjuvanttherapy. In our survey, a total of 1673/17241 cases (9.7%) were treated withneoadjuvant therapy, ranging from 2.9% to 23.6% according to different centres,showing heterogeneity in neoadjuvant treatment indications, even inmultidisciplinary breast units. Better resources should be engaged to achieve astandardised quality indicator for neoadjuvant treatment, and this indicatorcould be included among the European Society of Breast Cancer Specialists(EUSOMA) quality indicators. In the near future, we plan to develop a secondsurvey to better test improvements in the employment of neoadjuvant therapy afterthe expiry of the 2016 European Parliament deadline and after the 2017 St. GallenConference recommendations.Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and theEuropean Society of Surgical Oncology. All rights reserved.DOI: 10.1016/j.ejso.2018.03.018 PMID: 29653781  [Indexed for MEDLINE]